CAH
CAH
CAH
CAH NASDAQ
A report from zacks.com discusses Neurocrine's Crenessity gaining ground in CAH and questions how far sales can go. Alongside these developments, Cardinal Health Inc reports an annual revenue of $254,248,000,000 and a market cap of approximately $57.89 billion. The company also demonstrates a TTM EPS of roughly 7.26, a PE ratio of 34.0, and a free cash flow yield of about 7.82%.
Based on zacks.comNeurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
3,554 Shares in Cardinal Health, Inc. $CAH Bought by Connor Clark & Lunn Investment Management Ltd.
Cardinal Health (CAH) is a Top-Ranked Momentum Stock: Should You Buy?
Cardinal Health, Inc. $CAH Shares Bought by Algert Global LLC
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now
What to Know About the Latest Sale From Cardinal Health's Chief Accounting Officer
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Stonks with professional market data, charts beside chat, and your portfolio context.
Tape shows delayed public market data. Not investment advice.